Research programme: eye disorder therapies - Handok PharmaceuticalsAlternative Names: HL 3501; HL 5501; HL 5511; HL5521
Latest Information Update: 21 Aug 2014
At a glance
- Originator Handok Inc
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Age-related macular degeneration; Diabetic macular oedema; Glaucoma
Most Recent Events
- 21 Aug 2014 Early research is ongoing in South Korea
- 01 Oct 2013 Early research in Age-related macular degeneration, Diabetic macular oedema and Glaucoma in South Korea (unspecified route)